Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Santiago Grau & Carlos Rubio-Terrés. (2008) Pharmacoeconomics of linezolid. Expert Opinion on Pharmacotherapy 9:6, pages 987-1000.
Read now
Read now
S. Grau, J.M. Aguado, J. Mateu-De Antonio, P. González & A. Del Castillo. (2007) Economic Evaluation of Linezolid Versus Teicoplanin for the Treatment of Infections Caused by Gram-Positive Microorganisms in Spain. Journal of Chemotherapy 19:4, pages 398-409.
Read now
Read now
Articles from other publishers (20)
Vincent I. LauFeng XieJohn BasmajiDeborah J. CookRobert FowlerMichel KiflenEmily SirotichAlla IansavicheneSean M. BagshawM. Elizabeth WilcoxFrançois LamontagneNiall FergusonBram Rochwerg. (2021) Health-Related Quality-of-Life and Cost Utility Analyses in Critical Care: A Systematic Review*. Critical Care Medicine 49:4, pages 575-588.
Crossref
Crossref
M. Elizabeth WilcoxKelsey VaughanChristopher A. K. Y. ChongPeter J. NeumannChaim M. Bell. (2019) Cost-Effectiveness Studies in the ICU: A Systematic Review*. Critical Care Medicine 47:8, pages 1011-1017.
Crossref
Crossref
Po-Chang Lin, Bruce C.M. Wang, Richard Kim, Andrew Magyar, Chung-Chih Lai, Ya-Wen Yang & Yhu-Chering Huang. (2016) Estimating the cost-effectiveness of linezolid for the treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Taiwan. Journal of Microbiology, Immunology and Infection 49:1, pages 46-51.
Crossref
Crossref
Talitha I. Verhoef & Stephen Morris. (2015) Cost-effectiveness and Pricing of Antibacterial Drugs. Chemical Biology & Drug Design 85:1, pages 4-13.
Crossref
Crossref
Yan Wang, Yamin Zou, Jiao Xie, Taotao Wang, Xiaowei Zheng, Hairong He, Weihua Dong, Jianfeng Xing & Yalin Dong. (2014) Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis. European Journal of Clinical Pharmacology 71:1, pages 107-115.
Crossref
Crossref
C. J. Clancy, S. M. Bartsch, M. H. Nguyen, D. R. Stuckey, R. K. Shields & B. Y. Lee. (2014) A computer simulation model of the cost-effectiveness of routine Staphylococcus aureus screening and decolonization among lung and heart-lung transplant recipients. European Journal of Clinical Microbiology & Infectious Diseases 33:6, pages 1053-1061.
Crossref
Crossref
Seng C. Tan, Xue Wang, Benquan Wu, Hongjun Kang, Qiang Li, Yixi Chen, Chieh-I Chen, Petr Hajek, Dipen A. Patel & Xin Gao. (2014) Cost-Effectiveness of Linezolid versus Vancomycin among Patients with Methicillin-Resistant Staphylococcus aureus Confirmed Nosocomial Pneumonia in China. Value in Health Regional Issues 3, pages 94-100.
Crossref
Crossref
Francisco Javier Carrera-Hueso, Rafael Ferriols-Lisart, José A Carrera-Hueso, Jaime E Poquet Jornet, Carmen Escoms-Moreno, Auxiliadora Ramón-Barrios & Manuel Hernández Pérez. (2013) Coste-efectividad de doripenem o imipenem en la neumonía asociada al respirador. PharmacoEconomics Spanish Research Articles 10:4, pages 131-140.
Crossref
Crossref
José Manuel Rodríguez Barrios, Ferran Pérez Alcántara, Carlos Crespo Palomo, Paloma González García, Enrique Antón De Las Heras & Max Brosa Riestra. (2011) The use of cost per life year gained as a measurement of cost-effectiveness in Spain: a systematic review of recent publications. The European Journal of Health Economics 13:6, pages 723-740.
Crossref
Crossref
Allan J. Walkey, Max R. O'Donnell & Renda Soylemez Wiener. (2011) Linezolid vs Glycopeptide Antibiotics for the Treatment of Suspected Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia. Chest 139:5, pages 1148-1155.
Crossref
Crossref
Dilip Nathwani. (2009) Health economic issues in the treatment of drug-resistant serious Gram-positive infections. Journal of Infection 59, pages S40-S50.
Crossref
Crossref
E. De Cock, W. A. Krueger, S. Sorensen, T. Baker, J. Hardewig, S. Duttagupta, E. Müller, A. Piecyk, E. Reisinger & A. Resch. (2009) Cost-Effectiveness of Linezolid vs Vancomycin in Suspected Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia in Germany. Infection 37:2.
Crossref
Crossref
M. Bounthavong, D. I. Hsu & M. P. Okamoto. (2009)
Cost-effectiveness analysis of linezolid vs. vancomycin in treating methicillin-resistant
Staphylococcus aureus
complicated skin and soft tissue infections using a decision analytic model
. International Journal of Clinical Practice 63:3, pages 376-386.
Crossref
Crossref
Josep Darbà, G. Restovic & R. Arocho. (2013) Posicionamiento de pegfilgrastim en las tablas clasificatorias de España según coste por años de vida ajustados por calidad (AVAC) y coste por años de vida ganados (AVG). PharmacoEconomics Spanish Research Articles 5:3, pages 94-107.
Crossref
Crossref
Fredric M. Pieracci & Philip S. Barie. (2007) Article Commentary: Strategies in the Prevention and Management of Ventilator-Associated Pneumonia. The American Surgeon 73:5, pages 419-432.
Crossref
Crossref
Lynn Estes & Robert Orenstein. (2007) . Clinical Therapeutics 29:2, pages 381-383.
Crossref
Crossref
Andrew F Shorr. (2007) Epidemiology and Economic Impact??of Meticillin-Resistant Staphylococcus aureus. PharmacoEconomics 25:9, pages 751-768.
Crossref
Crossref
Dirk M. Elston. (2007) Community-acquired methicillin-resistant Staphylococcus aureus. Journal of the American Academy of Dermatology 56:1, pages 1-16.
Crossref
Crossref
S. Maisch, P. Friederich & A. E. Goetz. (2006) „Public access defibrillation“Public access defibrillation. Der Anaesthesist 55:12, pages 1281-1290.
Crossref
Crossref
Greg L Plosker & David P Figgitt. (2005) Linezolid. PharmacoEconomics 23:9, pages 945-964.
Crossref
Crossref